Cristiani Stelitano

Cristiani Stelitano

Auto-generated profile, based on publicly available information

Cristiani Stelitano

Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia, Rua Augusto Viana s/n, 40110-060 Salvador, BA, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2013 in ISRN Hematology
Verified
Journal Article
Open access
PDF file
LLLuzia Estela Menezes Luz
Luzia Estela Menezes Luz
MNMarinho Marques da Silva Neto
Marinho Marques da Silva Neto
ILIvana Luz
Ivana Luz
CSCristiani Stelitano
Cristiani Stelitano
ENEduardo Martins Netto
Eduardo Martins Netto
CBCarlos Brites
Carlos Brites
Despite the benefits of HAART, HIV-infected patients are increasingly affected by different malignancies. We compared a 5-year-period survival time and prognostic factors for HIV-1-infected individuals diagnosed with non-Hodgkin lymphomas (NHL) in a nested case-control study, with non-HIV-infected individuals in Salvador, Brazil. Survival time and prognostic factors were compared to HIV-negative patients. 31 cases (versus 63 controls) had a significantly more advanced NHL at diagnosis and lower mean CD4 count (26 cells/mm3) than controls. Mean overall survival (OS) was 35.8 versus 75.4 months, for cases and controls, respectively (P<0.001), while mean event-free survival time (EFS) was 34.5 months for cases, versus 68.8 for controls (P=0.002). Higher IPI, increased LDH levels, bone marrow infiltration, lower absolute lymphocyte counts (<1,000 cells/mm3), and type B symptoms were associated with a shorter survival time for cases. Although patients without poorer prognostic factors at baseline had an OS comparable to controls, the mean CD4 cell count for cases was similar for patients with favorable and nonfavorable response to therapy. Our findings suggest that HIV-1 infection is significantly associated with a shorter survival time for patients with NHL, independently of other predictive factors and of disease stage.